Automated breast ultrasound (ABUS) is as effective as MRI in breast cancer screening in women with dense breast tissue, researchers say.
Automated breast ultrasound (ABUS) is as effective as MRI in breast cancer screening in women with dense breast tissue, show results of a study published in the July/August issue of Journal of Diagnostic Medical Sonography. In addition, the ABU’s short examination time and ease of use may make it a practical choice in many situations.
For this preliminary study, researchers from Nova Southeastern University in Winter Springs, Fla., assessed 24 asymptomatic women with more than 50 percent breast density on digital mammography. Each woman underwent an ABUS exam, which was followed a week later by a 3D contrast breast MRI. After comparing the two examinations, the researchers found 15 malignant tumors and nine benign pathologies.
Comparable diagnostic reliability was observed between the ABUS and the MRI in differentiating benign from malignant breast lesions based on similar morphologic criteria.
ABUS is cleared for diagnostic use, but not specifically for screening in women with dense breasts. ABUS does have disadvantages, including the inability to compress the breast tissue and the ability to view tissue or lesion vascularity. However, advantages to the procedure include that it is not invasive and that it is simple to use with less technical training than an MRI requires, perhaps making it more viable to screen larger groups of people.
The authors concluded that ABUS is a promising cost-effective adjunct diagnostic modality to MRI in the evaluation women with increased breast density by digital mammography.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.